| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.034 | 0.8 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.036 | 0.8 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.034 | 0.8 |